Breaking News, Collaborations & Alliances

AbbVie, Anima Partner on mRNA Modulators Against Oncology and Immunology Targets

Anima will receive $42 million upfront and is eligible to receive as much as $540 million in option fees and R&D milestones across the three targets.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie and Anima Biotech entered a collaboration to discover and develop mRNA biology modulators for three targets across Oncology and Immunology. Anima will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets providing AbbVie exclusive rights to license and further develop and commercialize the programs.   Anima will receive $42 million upfront and may be eligible to receive as much as $540 million in option fees and R&D milestones a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters